TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39509148

Group type: EXPERIMENTAL
Intervention: Systematic immediate VKA reversal with 25 IU/kg of four-factor prothrombin complex concentrate (4f-PCC) before any investigation.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard-of-care reversal only if the initial cranial CT scan indicated ICH.
Number of subjects: 202
Study: 39509183

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39509229

Group type: EXPERIMENTAL
Intervention: Men reporting PMIEs on the MIQ-M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women reporting PMIEs on the MIES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender differences in PMIE reporting
Number of subjects: 0
Study: 39509231

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sertraline (pharmacotherapy)
Number of subjects: 200
Study: 39509248

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Descemet automated endothelial keratoplasty (DAEK)
Number of subjects: 4
Study: 39509246

Group type: EXPERIMENTAL
Intervention: 68Ga-MY6349 PET/CT
Number of subjects: 90
Study: 39509387

Group type: EXPERIMENTAL
Intervention: TyG index (elevated)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: TyG index (highest group > 10)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: TyG index (highest group)
Number of subjects: 1538
Study: 39509430

Group type: EXPERIMENTAL
Intervention: Syphilis screening during the first trimester (54%), second trimester (29%), and third trimester (13%).
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Syphilis diagnosed in the second or third trimester.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Pregnant women without healthcare insurance (25%).
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Newborns exposed to T. pallidum in utero.
Number of subjects: 147
Study: 39509672

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 583

Group type: COMPARATOR
Intervention: No axillary lymph node dissection (ALND)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 583
Study: 39509704

Group type: EXPERIMENTAL
Intervention: Risk-Reducing Salpingectomy and Oophorectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39509708

Group type: EXPERIMENTAL
Intervention: MAL-ADL-PDT (160mg/g MAL cream)
Number of subjects: 224
Study: 39509711

Group type: EXPERIMENTAL
Intervention: CAD4TB v7
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert HR
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB [sequential negative]
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: CRP-CAD4TB [sequential negative]
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB [sequential positive]
Number of subjects: 1392
Study: 39509838

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) every four weeks (Q4W)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) every two weeks (Q2W)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q4W (achieved CII)
Number of subjects: 121
Study: 39510242

Group type: EXPERIMENTAL
Intervention: Occlusal Splint (OS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A (BTX-A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both OS and BTX-A
Number of subjects: 60
Study: 39510247

Group type: EXPERIMENTAL
Intervention: Blue light exposure for 25 minutes daily for 5 or more days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Red light exposure for 25 minutes daily for 5 or more days (placebo)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Blue light exposure
Number of subjects: 43
Study: 39510322

Group type: EXPERIMENTAL
Intervention: 5xICS (inhaled corticosteroids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1xICS (inhaled corticosteroids)
Number of subjects: 0
Study: 39510519

Group type: EXPERIMENTAL
Intervention: 12 mm mini-implants
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 14 mm mini-implants
Number of subjects: 24
Study: 39510586

Group type: EXPERIMENTAL
Intervention: CD70-Targeted Immuno-PET/CT Imaging
Number of subjects: 0
Study: 39510727

Group type: EXPERIMENTAL
Intervention: Iron-containing supplements (mainly multivitamins) taken prepregnancy/early pregnancy
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Ferritin < 60 μg/L
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Ferritin < 15 μg/L
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Ferritin < 30 μg/L
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: sTfR > 4.4 mg/L
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: TBI < 0 mg/kg
Number of subjects: 629
Study: 39510769

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic genotype-guided statin prescription
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard-of-care statin prescription
Number of subjects: 225
Study: 39510773

Group type: EXPERIMENTAL
Intervention: Evidence-based leadership training group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional online training group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 119
Study: 39510778

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination hesitancy across survey waves
Number of subjects: 13571

Group type: EXPERIMENTAL
Intervention: Factors associated with vaccination willingness
Number of subjects: 13571

Group type: EXPERIMENTAL
Intervention: Perceived financial status
Number of subjects: 13571

Group type: EXPERIMENTAL
Intervention: Gender influence on vaccination willingness
Number of subjects: 13571
Study: 39510783

Group type: EXPERIMENTAL
Intervention: Wearable gadget to remind users to break sitting time, coupled with a brief health coaching session, pamphlet, and reminder messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39510786

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39510785

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local anaesthetic wound infiltration
Number of subjects: 100
Study: 39510784

Group type: EXPERIMENTAL
Intervention: Home-based, multimodal prehabilitation programme (exercise, nutrition and psychosocial support) supported through an online platform for 3-12 weeks.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard perioperative care
Number of subjects: 144
Study: 39510803

Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum (QL) block
Number of subjects: 153

Group type: COMPARATOR
Intervention: Transversus abdominus plane (TAP) block
Number of subjects: 153

Group type: COMPARATOR
Intervention: Opioid consumption at 24 hours
Number of subjects: 153

Group type: COMPARATOR
Intervention: Pain scores
Number of subjects: 153

Group type: COMPARATOR
Intervention: Opioid-related side effects
Number of subjects: 153
Study: 39510809

Group type: EXPERIMENTAL
Intervention: BB-PGA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BB-CAI
Number of subjects: 22

Group type: COMPARATOR
Intervention: BB
Number of subjects: 22
Study: 39511001

Group type: EXPERIMENTAL
Intervention: Laser hemorrhoidoplasty
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 48
Study: 39511164

Group type: EXPERIMENTAL
Intervention: benmelstobart (1200 mg) plus anlotinib (10 mg) plus paclitaxel (135 mg) for 4-6 cycles (21-day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: benmelstobart (1200 mg) plus anlotinib (10 mg) plus chemotherapy
Number of subjects: 0
Study: 39511203

Group type: EXPERIMENTAL
Intervention: EPA and DHA (2.7 g/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EPA and DHA (dose-dependent)
Number of subjects: 33
Study: 39511367

Group type: EXPERIMENTAL
Intervention: Machine learning models for one-year stroke prediction
Number of subjects: 26183

Group type: COMPARATOR
Intervention: Current clinical risk scores
Number of subjects: 26183
Study: 39511473

Group type: EXPERIMENTAL
Intervention: Delirium group (individuals exhibiting delirium at least once)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-delirium group (remainder of individuals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 0
Study: 39511476

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2-0.7 mcg/kg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 0
Study: 39511504

Group type: EXPERIMENTAL
Intervention: Giomer sealant with etching (intervention group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Giomer sealant without etching (control group)
Number of subjects: 52
Study: 39511506

Group type: EXPERIMENTAL
Intervention: High iron group
Number of subjects: 216

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 216
Study: 39511571

Group type: EXPERIMENTAL
Intervention: Toolkit strategy (education, redesign workbooks, online learning community, remote coaching)
Number of subjects: 20
Study: 39511611

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/d) with standard of care concurrent chemoradiotherapy (cCRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care concurrent chemoradiotherapy (cCRT) without metformin
Number of subjects: 0
Study: 39511631

Group type: EXPERIMENTAL
Intervention: Enhanced microeconomic intervention including 12 weekly educational group sessions, employment-focused mentoring, and an unconditional grant of US $1200.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care including US $250 in emergency assistance and peer support for legal gender affirmation.
Number of subjects: 0
Study: 39511648

Group type: EXPERIMENTAL
Intervention: Telemonitoring with decision support
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Telemonitoring without decision support
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 39511666

Group type: EXPERIMENTAL
Intervention: Structured, family-supported, patient-centred ACP programme (ACP-Family)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual ACP care (ACP-UC)
Number of subjects: 170
Study: 39511701

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39511777

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-every-6-months (PP6M)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Paliperidone palmitate once-every-3-months (PP3M)
Number of subjects: 702
Study: 39511789

Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Bipolar voltage (BV)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV) in CPVI alone cohort
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Unipolar voltage (UV) in CPVI plus cohort
Number of subjects: 375
Study: 39511836

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (SEMA and TRT)
Number of subjects: 25
Study: 39512280

Group type: EXPERIMENTAL
Intervention: ublituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: teriflunomide
Number of subjects: 0
Study: 39512729

Group type: EXPERIMENTAL
Intervention: biweekly counseling (120 min over 8 weeks)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: one-time check-in (30 min) with a dietitian
Number of subjects: 99
Study: 39512761

Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 48781

Group type: COMPARATOR
Intervention: Quadrivalent standard-dose, inactivated influenza vaccine (SD-IIV4)
Number of subjects: 48781
Study: 39512897

Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention (AAI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 39
Study: 39513018

Group type: EXPERIMENTAL
Intervention: RVGLS/PASP ratio
Number of subjects: 2865

Group type: EXPERIMENTAL
Intervention: HF with reduced ejection fraction
Number of subjects: 2865

Group type: EXPERIMENTAL
Intervention: HF with mildly reduced ejection fraction
Number of subjects: 2865

Group type: EXPERIMENTAL
Intervention: HF with preserved ejection fraction
Number of subjects: 2865

Group type: EXPERIMENTAL
Intervention: RVGLS/PASP ratio ≤0.32
Number of subjects: 2865
Study: 39513023

Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab (12 mg/day, total 60 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous alemtuzumab (12 mg/day, total 36 mg)
Number of subjects: 24
Study: 39513044

Group type: EXPERIMENTAL
Intervention: Home-based, repeated transcranial alternating current stimulation (tACS) sessions
Number of subjects: 7
Study: 39513186

Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 400 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 100 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SOC plus asunercept 25 mg
Number of subjects: 438

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 438
Study: 39513224

Group type: EXPERIMENTAL
Intervention: Sitravatinib
Number of subjects: 0
Study: 39513255

Group type: EXPERIMENTAL
Intervention: 12-week supervised, moderate-intensity exercise training program (3 h/wk)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 59
Study: 39513267

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous BNP (0.005 µg/kg per minute)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study: 39513363

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg p.o. daily with nivolumab 240 mg i.v. on days 1 and 15 of a 28-day cycle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 16
Study: 39513369

Group type: EXPERIMENTAL
Intervention: Reduced skeletal muscle mass (sarcopenia)
Number of subjects: 2810

Group type: COMPARATOR
Intervention: Preserved skeletal muscle mass
Number of subjects: 2810
Study: 39513379

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39513382

Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 0
Study: 39513407

Group type: EXPERIMENTAL
Intervention: GLPG3970 350 mg + Sulfasalazine 1,000 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GLPG3970 350 mg + Methotrexate 7.5 mg
Number of subjects: 23
Study: 39513526

Group type: EXPERIMENTAL
Intervention: Rituximab with or without prednisone
Number of subjects: 3720

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 3720

Group type: EXPERIMENTAL
Intervention: Rituximab followed by MMF for 500 days
Number of subjects: 3720

Group type: EXPERIMENTAL
Intervention: MMF and levamisole
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 3720

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Levamisole and prednisone
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Alkylating agents compared to cyclosporin
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Alkylating agents
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Alkylating agents compared to prednisone
Number of subjects: 3720
Study: 39513569

Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.2 mg/kg/week (high dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: PEG-rhGH 0.1 mg/kg/week (low dose)
Number of subjects: 96
Study: 39513754

Group type: EXPERIMENTAL
Intervention: Semorinemab
Number of subjects: 0
Study: 39513970

Group type: EXPERIMENTAL
Intervention: LPCN 1148
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 39513971

Group type: EXPERIMENTAL
Intervention: Active cTBS stimulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study: 39514000

Group type: EXPERIMENTAL
Intervention: DualRx (Acetazolamide + Eszopiclone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TripleRx (Acetazolamide + Eszopiclone + Venlafaxine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 39514025

Group type: EXPERIMENTAL
Intervention: 20 mg tamoxifen
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: 5 mg and 10 mg tamoxifen
Number of subjects: 824

Group type: COMPARATOR
Intervention: Control group (postmenopausal women)
Number of subjects: 824
Study: 39514027

Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 54
Study: 39514041

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 39514051

Group type: EXPERIMENTAL
Intervention: Camrelizumab (adjuvant therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin with Tislelizumab (induction therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor and CTLA4 inhibitor (anaplastic thyroid carcinoma)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR and VEGF inhibitors (intensification of dRCT in NPC)
Number of subjects: 0
Study: 39514247

Group type: EXPERIMENTAL
Intervention: EHR-based medication alerts for DOAC prescriptions
Number of subjects: 134
Study: 39514254

Group type: EXPERIMENTAL
Intervention: KIM sling
Number of subjects: 147

Group type: COMPARATOR
Intervention: TVT Exact sling
Number of subjects: 147
Study: 39514256

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Videoconference group
Number of subjects: 9
Study: 39514264

Group type: EXPERIMENTAL
Intervention: VACT-CP
Number of subjects: 42

Group type: COMPARATOR
Intervention: WL+TAU
Number of subjects: 42
Study: 39514267

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg/m2) combined with chemotherapy and cryoablation
Number of subjects: 0
Study: 39514431

Group type: EXPERIMENTAL
Intervention: Hybrid cochlear implant with electric-acoustic stimulation (EAS)
Number of subjects: 52
Study: 39514692

Group type: EXPERIMENTAL
Intervention: Plant-meat diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Animal meat diet
Number of subjects: 36
Study: 39514693

Group type: EXPERIMENTAL
Intervention: Fluid overload (any degree; >7%)
Number of subjects: 68196

Group type: EXPERIMENTAL
Intervention: Fluid depletion (<−7%)
Number of subjects: 68196

Group type: EXPERIMENTAL
Intervention: Hyponatremia (sodium <135 mmol/L)
Number of subjects: 68196

Group type: EXPERIMENTAL
Intervention: Hypernatremia (sodium >145 mmol/L)
Number of subjects: 68196

Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (≤138 mmol/L)
Number of subjects: 68196
Study: 39514718

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Home safety control group
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Greater variability in sleep onset timing
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Greater variability in sleep midpoint timing
Number of subjects: 143
Study: 39514777

Group type: EXPERIMENTAL
Intervention: Smartphone app-based self-management program (n = 25)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 46
Study: 39514845

Group type: EXPERIMENTAL
Intervention: NIV with active humidification
Number of subjects: 144

Group type: COMPARATOR
Intervention: HFNC
Number of subjects: 144
Study: 39514882

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBIs)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 708
Study: 39514895

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI) with cultural adaptations
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Facilitated initiation of medications for AUD
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 132
Study: 39514898

Group type: EXPERIMENTAL
Intervention: Opioid Overdose Education and Naloxone Distribution (OEND) training (n = 111)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (those who declined training, n = 193)
Number of subjects: 304
Study: 39515186

Group type: EXPERIMENTAL
Intervention: oVRcome mobile application (self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waitlist delayed treatment group
Number of subjects: 126
Study: 39515198

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-based regimen
Number of subjects: 35
Study: 39515347

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 19292

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 19292

Group type: COMPARATOR
Intervention: Pyrethroid only LLINs
Number of subjects: 19292
Study: 39515361

Group type: EXPERIMENTAL
Intervention: Problem Management for Moms (PM4M) programme, a ten-session treatment offered by phone or in person.
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Problem Management for Moms (PM4M) programme
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 265
Study: 39515374

Group type: EXPERIMENTAL
Intervention: Hippotherapy and the Equine Environment
Number of subjects: 0
Study: 39515522

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concomitant eosinophil-lowering therapy
Number of subjects: 28
Study: 39515580

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ultra-brief pulse right unilateral Electroconvulsive Therapy (ECT)
Number of subjects: 73
Study: 39515756

Group type: EXPERIMENTAL
Intervention: Rye-based diet
Number of subjects: 29
Study: 39515845

Group type: EXPERIMENTAL
Intervention: Online exposure and response prevention behavioural therapy for tics
Number of subjects: 224

Group type: COMPARATOR
Intervention: Online psychoeducation
Number of subjects: 224